Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06537596 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06537596 · ClinicalTrials.gov record · last posted 2026-08-14

89Zr-olaratumab Dosimetry in Participants With PDGFR Alpha Positive Solid Tumours and Soft Tissue Sarcoma

Study acronym: ZOLAR
StatusRecruiting
PhasePhase 1
Started2024-10-31
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
Soft Tissue Sarcoma (STS) is a cancer of soft tissues that often expresses Platelet-Derived Growth Factor Receptor (PDGFR)α, a potential therapeutic target. PDGFRα is also found in other advanced solid tumours. Olaratumab, a PDGFRα-targeted antibody, may be used to deliver radioactive isotopes for imaging or therapy. This first-in-human study will evaluate zirconium-89-labelled olaratumab (⁸⁹Zr-TLX300-CDx) for imaging in patients with STS, selected PDGFRα-positive solid tumours and identification of patients that may benefit from future treatments.

Protocol amendment history 2 changes detected by DataLookout

2026-08-15
Primary completion pushed: 2026-03 → 2027-10
2026-08-15
Completion pushed: 2026-08 → 2027-12
Trial Details
NCT Number NCT06537596
Lead Sponsor Telix Pharmaceuticals (Innovations) Pty Ltd
Conditions Soft Tissue Sarcoma, PDGFR Alpha Positive Solid Tumours
Enrollment 50 participants
Start Date 2024-10-31
Primary Completion 2027-10 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-08-14